Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.
Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences (NASDAQ: IART) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, before market open. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results.
Investors can access a live webcast through the company's investor relations website. Those wishing to participate in the call need to register to receive dial-in details and an individual pin. The company recommends joining 10 minutes before the start time. A replay of the webcast will be available on the company's investor website after the call.
Integra LifeSciences (Nasdaq: IART) has launched the Integra Institute, a new global medical education platform designed for healthcare professionals (HCPs). The digital platform offers on-demand learning resources focusing on surgical, neurologic, ENT, and regenerative care across the United States and EMEA regions.
The platform features curated content including on-demand webinars covering complex medical scenarios, surgical videos demonstrating latest techniques, and an events calendar for continuous learning and networking opportunities. The initiative aims to provide a comprehensive professional development resource for healthcare providers at various experience levels.
Dr. Said Azoury, plastic and reconstructive surgeon at the Hospital of the University of Pennsylvania, endorsed the platform's potential for facilitating convenient learning and collaboration. Healthcare professionals can access the platform by registering at institute.integralife.com.
A new economic study published in the Journal of Comparative Effectiveness Research demonstrates significant cost savings when using Integra's DuraSeal Polyethylene Glycol (PEG) hydrogel instead of fibrin glue in posterior cranial fossa surgeries. The analysis, conducted across five European countries (Belgium, France, Germany, Italy, and UK), shows cost savings ranging from €419 to €1,279 per patient, representing an average 22% cost reduction per procedure (15% in Italy).
The study is based on a prospective observational study of 200 patients and reveals that DuraSeal's effectiveness at preventing cerebrospinal fluid (CSF) leaks leads to reduced hospital stays and fewer post-surgical interventions. Despite higher upfront costs, DuraSeal proves to be a cost-effective alternative to fibrin glue in PCF surgery across European healthcare systems.
Integra LifeSciences (NASDAQ: IART) reported Q3 2024 financial results with revenues of $380.8 million, showing a 0.4% decrease on a reported basis and 8.6% decline organically compared to last year. The company posted a GAAP loss of $(0.14) per share, down from $0.24 in the prior year, while adjusted EPS fell to $0.41 from $0.76.
The Codman Specialty Surgical segment (~70% of revenues) reached $270.8 million with 1.0% reported growth, while Tissue Technologies (~30%) declined 3.6% to $110.1 million. The company updated its full-year 2024 guidance to $1.609-1.619 billion in revenue and adjusted EPS of $2.41-2.49.
Integra LifeSciences (NASDAQ: IART) has appointed Mojdeh Poul as its new president and CEO, effective January 6, 2025. Poul, who previously served as executive vice president and group president of 3M's $8.5B Global Healthcare Business, will succeed Jan De Witte. She brings extensive experience in healthcare business strategy, portfolio transformation, and commercial operations. Poul's background includes leadership positions at Medtronic and Boston Scientific, and she currently serves on the boards of Align Technology, iRhythm Technologies, and Stanley Black & Decker. Stuart Essig will temporarily serve as executive chairman before returning to his non-executive chairman role.
Integra LifeSciences Holdings (NASDAQ: IART), a leading global medical technology company, has announced it will release its third quarter 2024 financial results on Monday, November 4, 2024, before the market opens. Following the release, the company's management team will host a conference call at 8:30 a.m. ET to discuss the results.
Investors and interested parties can access a live webcast of the conference call through the Investors section of Integra's website at investor.integralife.com. Those planning to participate in the call are encouraged to register in advance to receive dial-in details and an individual pin. It is recommended to join the call 10 minutes before it starts. A webcast replay of the conference call will be made available on the company's Investors section following the event.
Halda Therapeutics, a biotech company developing RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics for cancer, has appointed Christian Schade as President, CEO, and Board member. Schade brings over 20 years of pharma and biotech industry experience, including leadership in clinical pipeline development and value-creating deals. Tim Shannon continues as Board Chairman.
Schade's appointment comes as Halda prepares to enter clinical trials, with the first RIPTAC therapeutic expected to begin trials in the first half of 2025. The company is focusing on developing therapies for prostate and breast cancer. Schade's previous roles include CEO of Aprea Therapeutics, Growth Partner at Flagship Pioneering, and executive positions at Novira, Omthera Pharmaceuticals, and Medarex.
Integra LifeSciences (NASDAQ: IART), a leading global medical technology company, has announced its participation in the 22nd Annual Morgan Stanley Healthcare Conference. Lea Knight, the company's chief financial officer, is scheduled to present on September 6, 2024, at 10:45am ET.
The presentation will be accessible via a live webcast on Integra LifeSciences' investor relations website. This event provides an opportunity for investors and analysts to gain insights into the company's recent developments, financial performance, and future outlook within the healthcare technology sector.
Integra LifeSciences' participation in this prestigious conference underscores its commitment to engaging with the investment community and showcasing its position in the medical technology market.
Integra LifeSciences (NASDAQ: IART), a global medical technology leader, has announced its participation in the 2024 Wells Fargo Healthcare Conference. Lea Knight, the company's chief financial officer, is scheduled to present on September 4, 2024, at 1:30 PM ET.
Investors and interested parties can access a live webcast of the presentation through Integra's investor relations website. This event provides an opportunity for stakeholders to gain insights into the company's current status and future prospects directly from its financial leadership.
The presentation at this prestigious healthcare conference underscores Integra's commitment to transparency and engagement with the investment community, potentially impacting its market position and stock performance.
Integra LifeSciences (NASDAQ: IART) has released its third Environmental, Social and Governance (ESG) report, highlighting the company's 2023 performance and ongoing efforts in line with its ESG strategy. Key achievements include:
Environmental: Recalculated Scope 1, 2, and 3 emissions and partnered with external consultants to identify energy reduction opportunities.
Social: Enhanced diversity and inclusion efforts by adding a new employee resource group and supporting diverse college students and graduates.
Governance: Revised Code of Conduct and strengthened anti-bribery and corruption programs.
The report aligns with the Global Reporting Index and Sustainability Accounting Standards Board Index, demonstrating Integra's commitment to creating healthier people, workplaces, and world.